Jubilant Pharmova Limited ('Company') today announced that the United States Food and Drug Administration (USFDA) has concluded the audit of the Jubilant HollisterStier General Partnership (JHSGP)'s contract manufacturing facility located in Montreal, Canada.

The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations.

JHSGP is a subsidiary of Jubilant HollisterStier Inc., USA, a step down subsidiary of Jubilant Pharma Limited, Singapore, and a wholly owned subsidiary of the Company.